Insider track record Other Across 13 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Explore the full record of transactions filed by Luke Miels. Director active across 1 company, notably GSK plc. Cumulatively, 53 disclosures have been published. Activity tracked since 12 October 2023. The latest transaction was filed on 14 April 2026 (Vesting). Regulator: RNS (LSE). The full history is free.
Declarations 53 total
● Chief Executive Officer · Executives · 14 Apr 2026 · GSK plc 1,178 shares @ £21.67 0.0000% mcap 0.1% of flow GB00BN7SWP63⌘ RNS:ca89baf1-aabf-4020-b0fe-d5c65c1b3a57-0 ● Chief Executive Officer · Executives · 9 Apr 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-4 Ideal exit: 4 Jan 2027 (T+270) ● Chief Executive Officer · Executives · 9 Apr 2026 · GSK plc 2 shares @ £21.34 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:5b5d692c-e307-4a46-a436-f5464b4ee34b-0 Ideal exit: 4 Jan 2027 (T+270) ● Chief Executive Officer · Executives · 13 Feb 2026 · GSK plc 245,716 shares 0
GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-0 ● Chief Executive Officer · Executives · 13 Feb 2026 · GSK plc 15,579 shares @ £21.6002 1.5% of flow GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-1 ● Chief Executive Officer · Executives · 12 Feb 2026 · GSK plc 27,962 shares @ £21.50 2.7% of flow GB00BN7SWP63⌘ RNS:6207777f-2477-470b-868f-21f92714189a-0 ● Chief Executive Officer · Executives · 12 Feb 2026 · GSK plc 463,662 shares @ £21.50 44.5% of flow GB00BN7SWP63⌘ RNS:586c5c74-54b9-425a-a37c-ba21836ecce7-0 ● Chief Executive Officer · Executives · 9 Feb 2026 · GSK plc 4,549 shares @ £22.114 0.5% of flow GB00BN7SWP63⌘ RNS:527591f3-f598-44b4-87bb-f5cfd91a36cb-1 ● Chief Executive Officer · Executives · 9 Feb 2026 · GSK plc 60,334 shares 0
GB00BN7SWP63⌘ RNS:527591f3-f598-44b4-87bb-f5cfd91a36cb-0 ● Chief Executive Officer · Executives · 10 Feb 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:8df504c6-f415-410b-a190-e5ddcfc0debe-0 ● Chief Executive Officer · Executives · 8 Jan 2026 · GSK plc 3 shares @ £18.9433 0.0% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-0 Ideal exit: 5 Oct 2026 (T+270) ● Chief Executive Officer · Executives · 9 Jan 2026 · GSK plc 1,462 shares @ £18.91 0.1% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-24 ● Chief Commercial Officer · Executives · 10 Oct 2025 · GSK plc 1,670 shares @ £16.40 0.2% of flow GB00BN7SWP63⌘ RNS:5862277-5 ● Chief Commercial Officer · Executives · 9 Oct 2025 · GSK plc 3 shares @ £16.3933 0.0% of flow GB00BN7SWP63⌘ RNS:5859068-4 Ideal exit: 6 Jul 2026 (T+270) ● Chief Commercial Officer · Executives · 10 Jul 2025 · GSK plc 3 shares @ £14.4433 0.0% of flow GB00BN7SWP63⌘ RNS:5737340-13 Ideal exit: 6 Apr 2026 (T+270) ● Chief Commercial Officer · Executives · 10 Jul 2025 · GSK plc 1,862 shares @ £14.545 0.2% of flow GB00BN7SWP63⌘ RNS:5737340-24 ● Chief Commercial Officer · Executives · 16 Apr 2025 · GSK plc 2,098 shares @ £12.75 0.2% of flow GB00BN7SWP63⌘ RNS:5622701-5 ● Chief Commercial Officer · Executives · 10 Apr 2025 · GSK plc 0
GB00BN7SWP63⌘ RNS:5617047-13 Ideal exit: 5 Jan 2026 (T+270) ● Chief Commercial Officer · Executives · 10 Apr 2025 · GSK plc 3 shares @ £13.1267 0.0% of flow GB00BN7SWP63⌘ RNS:5615070-13 Ideal exit: 5 Jan 2026 (T+270) ● Chief Commercial Officer · Executives · 17 Feb 2025 · GSK plc 298,713 shares @ £14.35 39.7% of flow GB00BN7SWP63⌘ RNS:5546836-5 ● Chief Commercial Officer · Executives · 17 Feb 2025 · GSK plc 36,562 shares @ £14.35 4.9% of flow GB00BN7SWP63⌘ RNS:5546650-5 ● Chief Commercial Officer · Executives · 18 Feb 2025 · GSK plc 14,763 shares @ £14.2531 2.0% of flow GB00BN7SWP63⌘ RNS:5546637-8 ● Chief Commercial Officer · Executives · 18 Feb 2025 · GSK plc 208,808 shares 0
GB00BN7SWP63⌘ RNS:5546637-7 ● Chief Commercial Officer · Executives · 17 Feb 2025 · GSK plc 26,851 shares 0
GB00BN7SWP63⌘ RNS:5546603-10 ● Chief Commercial Officer · Executives · 17 Feb 2025 · GSK plc 618 shares @ £14.195 0.1% of flow GB00BN7SWP63⌘ RNS:5546603-11 25 of 53 declarations
Load more (28 remaining) About Luke Miels Luke Miels is Chief Executive Officer of GSK plc and joined the Board on 1 January 2026. GSK says he joined the company in 2017 as Chief Commercial Officer, after senior roles at AstraZeneca, Roche, and Sanofi-Aventis. GSK also says he holds a Bachelor of Science in Biology from Flinders University and an MBA from Macquarie University. Sources: https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/luke-miels/